Guidance
← 실적 발표
01
02
03
04 05 06
톤
AI
자본지출
A1 A2 A3
BMY
FY2026 Q1
개선
Bristol-Myers Squibb Company 실적 발표
Buzzberg 분석
Guidance tracking toward top end of 2026 ranges
Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%).
Buzzberg 분석 Guidance tracking toward top end of 2026 ranges Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%). 전체 분석 보기분석 접기
Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%).
- The company reaffirmed full-year 2026 guidance and stated it is tracking towards the upper end of its revenue and EPS ranges.
- Management expressed high confidence in the late-stage pipeline, particularly in upcoming readouts for milvexian (AFib/stroke) and Cobenfi (Alzheimer's psychosis), which are expected by year-end.
- The launch of Qvantig (subcutaneous Opdivo) is progressing well, with over 10% conversion from IV in the US and a target of 30-40% within two years.
GROWTH_PORTFOLIO 매출$6.2B보고값
매출$11.489B-8% 전분기 대비
주당순이익(EPS)$1.58+25% 전분기 대비
매출총이익률70.22%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Pipeline
Late-2026 pivotal readouts to define/de-risk growth
Pipeline
Milvexian hailed as true blockbuster opportunity
핵심 내용 3개 더 보기
Cell Mods
Cell mod program advancing toward first market entry
Oncology Strategy
Pumitamig strategy: replace PD-1 and expand beyond
Capital Allocation
BD remains size-agnostic with financial flexibility
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| GROWTH_PORTFOLIO 매출 | $6.2B | 보고값 |
| 매출 | $11.489B | -8% 전분기 대비 |
| 주당순이익(EPS) | $1.58 | +25% 전분기 대비 |
| 매출총이익률 | 70.22% | 보고값 |
| 영업이익률 | 29.29% | 보고값 |
| 잉여현금흐름 | $0.757B | -53% 전분기 대비 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management repeatedly emphasized execution, momentum, and tracking toward the upper end of guidance, with conviction in late-stage pipeline catalysts.
경영진의 AI 분석
AI is discussed as an internal R&D productivity lever, not a product/monetization driver. Management cited broader use of AI tools, lab automation, and partnerships to streamline clinical operations, compress development timelines, and improve trial design.
투자 및 생산능력
No explicit capex numbers were provided. Management qualitatively noted increased investment in core R&D infrastructure, including AI tools and laboratory automation, enabled partly by the remaining $2 billion Strategic Productivity Initiative savings.
아래에 언급된 기업 1개 모두 표시
기업발표 이후 수익률
파트너
파트너
Christian Massachese
BMY's partnership with BNTX on pimmitimig (a PD-1/VEGF bispecific) is progressing well, highlighting a strong collaborative relationship that could drive value for both companies.
근거
“the partnership with BioNTech is moving very well because we are progressing the development of this drug with speed.”
외부 신호
공급망 알파 · 3발표 이후 수익률
Wholesaler inventory dynamics for Eliquis are expected to reverse in Q2, with a build in Q1 and anticipated drawdown, which could smooth out reported revenue trends.
근거
“We also saw some wholesaler inventory build in the first quarter. We anticipate this build to reverse in the second quarter.”
A 10% conversion of Opdivo patients to Qvantig (subcutaneous) has already been achieved in the US, with a target of 30-40% conversion over the next two years.
근거
“we've now delivered over 10% conversion from IV to Cuvantig in the U.S. in just over a year on the market and we're tracking well against our expectations and we remain confident in our expectation that physicians will convert approximatel…”
BMY is planning a new, more focused study in non-obstructive HCM, indicating a strategic pivot based on learnings from the Odyssey study, potentially enabling a more targeted and successful development path for Camzyos.
근거
“So I want to announce that we are planning now to run a new, more focused study in non-obstructive HCM. And then, of course, the detail of it will be highlighted in clinicaltri.gov while we are progressing this work.”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 1개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.